Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia.

Data on long-term outcomes and biological drivers associated with depth of remission after BCL2 inhibition by venetoclax in the treatment of chronic lymphocytic leukemia (CLL) are limited. In this open-label parallel-group phase-3 study, 432 patients with previously untreated CLL were randomized (1:1) to receive either 1-year venetoclax-obinutuzumab (Ven-Obi, 216 patients) or chlorambucil-Obi (Clb-Obi, 216 patients) therapy (NCT02242942). The primary endpoint was investigator-assessed progression-free survival (PFS); secondary endpoints included minimal residual disease (MRD) and overall survival.

Presentation of metastatic renal cell carcinoma as a lip lesion.

We present a case of a 64-year-old gentleman who developed a renal cell carcinoma (RCC) metastasis to his lower lip following successful treatment of the primary tumour. RCC is a common kidney tumour but skin metastases are considered rare. The authors describe the findings of this case and discuss the presentation, investigations and management of RCC skin lesions.